The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: From molecular mechanism to future potential

IF 5.9 3区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Non-coding RNA Research Pub Date : 2024-05-20 DOI:10.1016/j.ncrna.2024.05.005

Mohaddese Malek Mohammadi , Hamidreza Rismanchi , Shakiba Esmailzadeh , Aryan Farahani , Neda Hedayati , Mina Alimohammadi , Alireza Mafi , Najma Farahani , Kiavash Hushmandi

{"title":"The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: From molecular mechanism to future potential","authors":"Mohaddese Malek Mohammadi , Hamidreza Rismanchi , Shakiba Esmailzadeh , Aryan Farahani , Neda Hedayati , Mina Alimohammadi , Alireza Mafi , Najma Farahani , Kiavash Hushmandi","doi":"10.1016/j.ncrna.2024.05.005","DOIUrl":null,"url":null,"abstract":"<div><p>Ovarian cancer (OC) is the most common cause of death in female cancers. The prognosis of OC is very poor due to delayed diagnosis and identification of most patients in advanced stages, metastasis, recurrence, and resistance to chemotherapy. As chemotherapy with platinum-based drugs such as cisplatin (DDP) is the main treatment in most OC cases, resistance to DDP is an important obstacle to achieving satisfactory therapeutic efficacy. Consequently, knowing the different molecular mechanisms involved in resistance to DDP is necessary to achieve new therapeutic approaches. According to numerous recent studies, non-coding RNAs (ncRNAs) could regulate proliferation, differentiation, apoptosis, and chemoresistance in many cancers, including OC. Most of these ncRNAs are released by tumor cells into human fluid, allowing them to be used as tools for diagnosis. CircRNAs are ncRNA family members that have a role in the initiation, progression, and chemoresistance regulation of various cancers. In the current study, we investigated the roles of several circRNAs and their signaling pathways on OC progression and also on DDP resistance during chemotherapy.</p></div>","PeriodicalId":37653,"journal":{"name":"Non-coding RNA Research","volume":"9 4","pages":"Pages 1280-1291"},"PeriodicalIF":5.9000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468054024000921/pdfft?md5=8ceb2cb64bdaea90214aa4b5192cec44&pid=1-s2.0-S2468054024000921-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Non-coding RNA Research","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468054024000921","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Ovarian cancer (OC) is the most common cause of death in female cancers. The prognosis of OC is very poor due to delayed diagnosis and identification of most patients in advanced stages, metastasis, recurrence, and resistance to chemotherapy. As chemotherapy with platinum-based drugs such as cisplatin (DDP) is the main treatment in most OC cases, resistance to DDP is an important obstacle to achieving satisfactory therapeutic efficacy. Consequently, knowing the different molecular mechanisms involved in resistance to DDP is necessary to achieve new therapeutic approaches. According to numerous recent studies, non-coding RNAs (ncRNAs) could regulate proliferation, differentiation, apoptosis, and chemoresistance in many cancers, including OC. Most of these ncRNAs are released by tumor cells into human fluid, allowing them to be used as tools for diagnosis. CircRNAs are ncRNA family members that have a role in the initiation, progression, and chemoresistance regulation of various cancers. In the current study, we investigated the roles of several circRNAs and their signaling pathways on OC progression and also on DDP resistance during chemotherapy.

查看原文本刊更多论文

环状 RNA 在卵巢癌顺铂耐药性中的新作用：从分子机制到未来潜力

卵巢癌（OC）是女性癌症中最常见的死因。卵巢癌的预后很差，这是因为大多数患者被延误诊断和发现时已是晚期，还有转移、复发和对化疗的耐药性。由于顺铂（DDP）等铂类药物化疗是大多数 OC 病例的主要治疗手段，因此对 DDP 产生耐药性是取得满意疗效的重要障碍。因此，了解导致对 DDP 产生耐药性的不同分子机制对于找到新的治疗方法非常必要。根据最近的大量研究，非编码 RNA（ncRNA）可调控包括 OC 在内的多种癌症的增殖、分化、凋亡和化疗耐药性。这些 ncRNA 大多由肿瘤细胞释放到人体液中，可用作诊断工具。CircRNAs是ncRNA家族成员，在各种癌症的发生、发展和化疗抗性调控中发挥作用。在本研究中，我们探讨了几种circRNA及其信号通路在OC进展和化疗期间DDP耐药性中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Non-coding RNA Research Medicine-Biochemistry (medical)

CiteScore

7.70

自引率

6.00%

发文量

审稿时长

49 days

期刊介绍： Non-coding RNA Research aims to publish high quality research and review articles on the mechanistic role of non-coding RNAs in all human diseases. This interdisciplinary journal will welcome research dealing with all aspects of non-coding RNAs-their biogenesis, regulation and role in disease progression. The focus of this journal will be to publish translational studies as well as well-designed basic studies with translational and clinical implications. The non-coding RNAs of particular interest will be microRNAs (miRNAs), small interfering RNAs (siRNAs), small nucleolar RNAs (snoRNAs), U-RNAs/small nuclear RNAs (snRNAs), exosomal/extracellular RNAs (exRNAs), Piwi-interacting RNAs (piRNAs) and long non-coding RNAs. Topics of interest will include, but not limited to: -Regulation of non-coding RNAs -Targets and regulatory functions of non-coding RNAs -Epigenetics and non-coding RNAs -Biological functions of non-coding RNAs -Non-coding RNAs as biomarkers -Non-coding RNA-based therapeutics -Prognostic value of non-coding RNAs -Pharmacological studies involving non-coding RNAs -Population based and epidemiological studies -Gene expression / proteomics / computational / pathway analysis-based studies on non-coding RNAs with functional validation -Novel strategies to manipulate non-coding RNAs expression and function -Clinical studies on evaluation of non-coding RNAs The journal will strive to disseminate cutting edge research, showcasing the ever-evolving importance of non-coding RNAs in modern day research and medicine.